User login
Key clinical point: Letrozole-associated controlled ovarian hyperstimulation (LetCOH) was as effective as conventional controlled ovarian hyperstimulation (cCOH) for fertility preservation (FP) and minimized the risk for supraphysiologic estrogen exposure; however, more patients in the LetCOH group relapsed.
Major finding: In the LetCOH vs cCOH group, estradiol peak at the ovulation trigger was lower, but oocyte maturation rates were significantly higher (P < .001), and the final number of mature oocytes collected was comparable (P = .281). Disease recurrence occurred in 17% and 7.2% of patients in the LetCOH and cCOH groups, respectively.
Study details: Findings are from a retrospective observational study including 97 patients with nonmetastatic breast cancer (BC) who were ≤ 40 years old and had undergone FP with LetCOH (n = 41) or cCOH (n = 56) before receiving chemotherapy.
Disclosures: This study did not receive any funding. I Demeestere declared receiving honoraria and support and serving as a consultant or advisor for several sources outside this work.
Source: Goldrat O et al. Efficacy and safety of controlled ovarian hyperstimulation with or without letrozole for fertility preservation in breast cancer patients: A multicenter retrospective study. Eur J Cancer. 2022;174:134-141 (Aug 20). Doi: 10.1016/j.ejca.2022.07.017
Key clinical point: Letrozole-associated controlled ovarian hyperstimulation (LetCOH) was as effective as conventional controlled ovarian hyperstimulation (cCOH) for fertility preservation (FP) and minimized the risk for supraphysiologic estrogen exposure; however, more patients in the LetCOH group relapsed.
Major finding: In the LetCOH vs cCOH group, estradiol peak at the ovulation trigger was lower, but oocyte maturation rates were significantly higher (P < .001), and the final number of mature oocytes collected was comparable (P = .281). Disease recurrence occurred in 17% and 7.2% of patients in the LetCOH and cCOH groups, respectively.
Study details: Findings are from a retrospective observational study including 97 patients with nonmetastatic breast cancer (BC) who were ≤ 40 years old and had undergone FP with LetCOH (n = 41) or cCOH (n = 56) before receiving chemotherapy.
Disclosures: This study did not receive any funding. I Demeestere declared receiving honoraria and support and serving as a consultant or advisor for several sources outside this work.
Source: Goldrat O et al. Efficacy and safety of controlled ovarian hyperstimulation with or without letrozole for fertility preservation in breast cancer patients: A multicenter retrospective study. Eur J Cancer. 2022;174:134-141 (Aug 20). Doi: 10.1016/j.ejca.2022.07.017
Key clinical point: Letrozole-associated controlled ovarian hyperstimulation (LetCOH) was as effective as conventional controlled ovarian hyperstimulation (cCOH) for fertility preservation (FP) and minimized the risk for supraphysiologic estrogen exposure; however, more patients in the LetCOH group relapsed.
Major finding: In the LetCOH vs cCOH group, estradiol peak at the ovulation trigger was lower, but oocyte maturation rates were significantly higher (P < .001), and the final number of mature oocytes collected was comparable (P = .281). Disease recurrence occurred in 17% and 7.2% of patients in the LetCOH and cCOH groups, respectively.
Study details: Findings are from a retrospective observational study including 97 patients with nonmetastatic breast cancer (BC) who were ≤ 40 years old and had undergone FP with LetCOH (n = 41) or cCOH (n = 56) before receiving chemotherapy.
Disclosures: This study did not receive any funding. I Demeestere declared receiving honoraria and support and serving as a consultant or advisor for several sources outside this work.
Source: Goldrat O et al. Efficacy and safety of controlled ovarian hyperstimulation with or without letrozole for fertility preservation in breast cancer patients: A multicenter retrospective study. Eur J Cancer. 2022;174:134-141 (Aug 20). Doi: 10.1016/j.ejca.2022.07.017